Economic Evaluation of Pediatric Cancer Treatment: A Systematic Literature Review

@article{Russell2013EconomicEO,
  title={Economic Evaluation of Pediatric Cancer Treatment: A Systematic Literature Review},
  author={Heidi V. Russell and Janki M Panchal and Helena M. VonVille and Luisa Franzini and J. Michael Swint},
  journal={Pediatrics},
  year={2013},
  volume={131},
  pages={e273 - e287}
}
OBJECTIVE: Although there is a growing national focus on health care cost containment and accountability in resource utilization, childhood cancer therapy costs continue to increase without proportionate survival improvements. Economic evaluations (EEs) such as cost and/or cost effectiveness analysis may identify areas to improve resource efficiency. This review aims to identify and characterize the EE studies performed in this field. METHODS: We performed a structured literature search of the… 

Figures and Tables from this paper

Cost and cost-effectiveness of childhood cancer treatment in low-income and middle-income countries: a systematic review

A systematic review of existing evidence on the costs and cost-effectiveness of treating childhood cancers in LMICs suggests that even if all relevant inputs are included, LMIC childhood cancer treatment is consistently very cost-effective.

Economics of Pediatric Cancer in Four Eastern Mediterranean Countries: A Comparative Assessment

The available economic evidence on pediatric cancer care in the four countries is limited to resource availability and, to an extent, patient outcomes, with a substantial gap in information on drug quality, service provision efficiency, and cost-effectiveness.

Systematic review of costs and cost-effectiveness of treatment for relapsed/refractory acute leukemia in children and young adults

A systematic review was conducted to summarize health-economic evidence about costs/cost-effectiveness of treating r/r acute leukemia in children/young adults and found recommendations to deliver cost-effective treatments in real-world contexts, with implications for healthcare policy and practice.

Evaluating Early Case Capture of Pediatric Cancers in Seven Central Cancer Registries in the United States, 2013

Although challenges related to timeliness and increased work burden remain, indications suggest that researchers may reliably use these data for pediatric cancer studies as well as reflect national data overall with differences in several data elements.

Sustainable care for children with cancer: a Lancet Oncology Commission.

Bending the Cost Curve in Childhood Cancer

The aims of this review are to provide stakeholders with an overview of the drivers of financial costs of childhood cancer and to identify possible directions to curb or decrease these costs.

The cost of nephroblastoma treatment in South Africa: A very cost-effective investment with guidelines for the rest of Africa

The cost of investigation and treatment of nephroblastoma remains a challenge everywhere, but especially in Africa, but it is a very cost-effective disease to treat and children in Africa should not be denied treatment.

The clinical and financial impact of a pediatric surgical neuro-oncology clinical trial

Pediatric surgical trials are rare and the impact of such trials on the institutions in which they are conducted is unknown. The purpose of this study was to analyze the clinical and financial impact

Individual and Nationwide Costs for Cancer Care During the First Year After Diagnosis Among Children, Adolescents, and Young Adults in Japan.

It was showed that cancer treatments for both children and AYAs were highly cost-intensive in Japan and suggested the need for further financial and policy evaluation.

References

SHOWING 1-10 OF 90 REFERENCES

The cost of childhood cancer from the family's perspective: A critical review

The objectives were to systematically review the literature and identify research and clinical implications, and strategies for enhancing the quality of childhood cancer cost of illness research are presented.

A structured review of studies on health-related quality of life and economic evaluation in pediatric acute lymphoblastic leukemia.

HRQL measures provide not only important information on the improvements offered by new therapies but also an outcome measure for economic evaluations, and should be included in the design of most future trials.

Economic evaluation of treatments for cancer in childhood.

Transferability of health technology assessments and economic evaluations: a systematic review of approaches for assessment and application

The proposed approaches and the factors used for assessing geographic transferability potential have varied substantially across the papers reviewed, and most promising is the identification of an extensive checklist of critical and noncritical factors in determining transferable potential.

Cost-effectiveness of pharmacogenomics in clinical practice: a case study of thiopurine methyltransferase genotyping in acute lymphoblastic leukemia in Europe.

The model has established that TPMT testing in ALL patients has a favorable cost-effectiveness ratio and should be seriously considered as an integral part of healthcare prior to the initiation of therapy with thiopurine drugs.

Methods for the Economic Evaluation of Health Care Programmes, Second Edition

The role of health economics is becoming firmly established in the evaluation of health care programs and can serve as a basic text for students hoping to understand the complex methodologies of economic evaluation.

The medical care cost of childhood and adolescent cancer in Manitoba, 1990-1995.

Estimation of the medical care costs of childhood and adolescent cancer in Manitoba found that the average cost for the first, second and third year following diagnosis was $50,902.

Cost-effectiveness of Outpatient Management for Febrile Neutropenia in Children With Cancer

Clinical data suggest, however, that outpatient management might be a safe and efficacious alternative for patients with low-risk FN episodes, and the substantially higher costs of inpatient management cannot be justified on the basis of safety and efficacy considerations or patient/parent preferences.

Use of Randomised Controlled Trials for Producing Cost-Effectiveness Evidence

Formal requirements for wholly stochastic cost-effectiveness evidence based on the standard frequentist paradigm have the potential to increase the size, duration and number of RCTs significantly and hence the costs and timelines associated with new product development.

Principles and practice of pediatric oncology

The fourth edition of Principles and Practice of Pediatric Oncology meets all the challenges of bringing the knowledge of traditional clinical paediatric oncology together with the information and technologies that are likely to change the authors' approach to childhood cancer.
...